Daniel Tassé is an experienced pharmaceutical executive, with a 30-year record of building, growing, and leading global pharmaceutical businesses and extensive experience bringing innovative therapies to pediatric patients. His deep regulatory and commercial experience have enabled him to bring ground-breaking therapies to patients and deliver strong returns to shareholders.
Prior to joining DBV, Daniel was Chairman and CEO of Alcresta, a pediatric-focused rare disease biotechnology company. During his tenure, Tassé recapitalized and rebuilt the company to ensure the successful launch of its first product, RELiZORB, a digestive enzyme cartridge that is indicated for use in pediatric patients. Before joining Alcresta, he was Chairman and CEO of Ikaria, which develops drugs and devices for critically ill patients. Daniel evolved Ikaria’s business model, driving significant sales and earnings growth, while also expanding operations into Asia. He also transformed the company into a fully integrated drug and device company, spurring R&D-based innovation to build a rich pipeline of critical care products. In April 2015, Ikaria was acquired by Mallinckrodt for $2.3 billion.
He holds a B.Sc. in Biochemistry from Université de Montréal and is fluent in both French and English.